Stress caused by family structure changes in infancy can triple psoriasis risk later in life

New longitudinal research reveals that severe stress caused by changes in family structure like divorce or separation ...
WDAF-TV

Arcutis Submits Supplemental New Drug Application for ZORYVE® (roflumilast) Cream 0.3% to Expand Indication for Treatment of Plaque Psoriasis in Children Ages 2 to 5

If approved, ZORYVE cream would be the first and only topical PDE4 inhibitor indicated for plaque psoriasis in children as young as 2, offering patients and caregivers an important alternative to ...
News-Medical.Net on MSN

Stressful life factors early in life may triple the risk of developing psoriasis later

New longitudinal research reveals that severe stress caused by changes in family structure like divorce or separation ...
KXAN

U.S. FDA approves TREMFYA® (guselkumab) for the treatment of pediatric plaque psoriasis and active psoriatic arthritis, marking a first and only approval for an IL-23 inhibitor

"Despite advancements in the treatment of pediatric plaque psoriasis and active psoriatic arthritis, there continues to be a significant gap in available therapies for these debilitating ...
Pharmaceutical Technology

J&J gets FDA approval for Tremfya in paediatric psoriasis

Johnson & Johnson's Tremfya is the first IL-23 inhibitor to gain FDA approval in a paediatric population for plaque psoriasis ...

How to tell the difference between eczema and psoriasis and get the right treatment

Eczema and psoriasis come with similar symptoms and therefore can be easy to confuse. Here's how to differentiate the two.
European Medical Journal

Biologic Therapy Shortens Hospital Stay in Pediatric GPP

Children with moderate-to-severe generalized pustular psoriasis showed faster recovery, shorter hospital stays, and lower ...
Morningstar

U.S. FDA approves TREMFYA® (guselkumab) for the treatment of pediatric plaque psoriasis and active psoriatic arthritis, marking a first and only approval for an IL-23 inhibitor

TREMFYA® is now approved for pediatric patients living with moderate to severe plaque psoriasis, who are candidates for systemic therapy or phototherapy, and active psoriatic arthritis in children six ...
Nasdaq

Arcutis Submits Supplemental New Drug Application for ZORYVE® (roflumilast) Cream 0.3% to Expand Indication for Treatment of Plaque Psoriasis in Children Ages 2 to 5

WESTLAKE VILLAGE, Calif., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in ...